A survivorship benefit for self-insured employers
A cancer survivorship benefit covers the period your health plan and your EAP both leave alone: the two years after treatment ends. Employees enroll privately and keep their own record. You receive aggregate reach and engagement only. It is educational and non-diagnostic, and it is designed to route people back to the plan rather than around it.
This page has two halves on purpose. The first is written to be forwarded to whoever raised the problem. The second answers what the person holding the budget asks once it lands on their desk.
The case, in one section
What employees actually get
More employees finish cancer treatment every year and go back to work, and almost every benefit built for cancer stops at the point treatment ends. That is the point most survivors describe as the hardest: the appointments that structured the last year disappear, the side effects do not, and the expectation from everyone around them is that it is over.
A survivorship benefit is what fills that. Concretely, for the employee:
Somewhere for the months nobody schedules
Treatment ends, the appointments stop, and most people describe that as the hardest part rather than the relief they expected. Short check-ins across the seven domains of survivorship give the weeks after treatment a shape, and give the person something to look at other than how they feel today.
A record instead of a memory
Patterns build up over months rather than being reconstructed in a ten minute appointment. Fatigue, sleep, cognition, hormone therapy side effects, mood, activity: all of it logged as it happened, by the person it happened to.
Something to bring to the oncologist
Before a follow-up, the check-ins become a short, doctor-ready summary of what has changed and what the person wanted to raise. The appointment was happening anyway, and it gets sharper.
A way to pace going back to work
Energy and cognition tracked across the weeks either side of a return, so a phased schedule is based on how someone is actually doing rather than an optimistic guess made while still on treatment.
None of it is diagnostic. It does not detect recurrence, predict recurrence, or replace anyone's oncology team, and it should never be presented internally as though it does. What it does is make the invisible part of recovery visible to the person going through it, and give them something concrete to bring to the people who can act on it. Our page on returning to work after cancer covers the return-to-work piece from the employee's side.
How privacy works
Employees enroll themselves. Nobody in HR enrolls anyone, and nobody in HR is told who did. What a participant records is theirs, and the only person who sees it in full is the participant, plus whoever they choose to show it to, which is usually their oncologist.
The employer receives aggregate reach and engagement. How many eligible people enrolled, and how many are still checking in at three months and at six. Nothing that identifies an individual or their health status, at any population size.
The test worth applying during evaluation, to us and to anyone else on your list: ask for a sample of the actual program-level report and read it as though a named colleague were in it. Our privacy policy sets out how data is handled, and our team will walk your privacy and security reviewers through the specifics during evaluation.
For the approver
The six questions that get asked at sign-off
These are the ones that come back after the clinical champion has already said yes. Short answers, so the person forwarding this does not have to write them.
- Does it overlap with the health plan?
- No. The plan pays for clinical care and surveillance. This covers the period between those appointments, and it points people back to the plan rather than around it.
- Does it overlap with the EAP?
- No. The EAP handles short-term counseling and life logistics. This is structured, cancer-specific support across a multi-year window, and it refers to the EAP where that is the right answer.
- What do we see?
- Aggregate reach and engagement. How many eligible people enrolled, and how many are still checking in at three and six months. Nothing that identifies an individual or their health status, ever.
- What do we have to run?
- Nothing operationally. There is no dashboard for HR to monitor and no case load. Employees enroll themselves from a communication you send once.
- What is the evidence?
- The product is being studied in an IRB-approved feasibility study within a large health system's survivorship program. That is feasibility work, and we will present it as feasibility work. Anyone offering you outcomes claims at this stage of the category is overselling.
- What happens if it does not work?
- You find out at the end of a time-boxed pilot, against criteria you set before it started. That is the whole reason to run one.
How a pilot is structured
Take one population segment rather than the whole workforce, open a defined enrollment window, and agree what the review at the end is measuring before anyone enrolls. Reach and sustained participation are the two numbers worth agreeing on. Satisfaction scores at week one will look good and will tell you nothing.
Keep the success criteria written down. The most common way a pilot fails is not disappointing results but a disagreement three months later about what it was meant to show, and that is entirely avoidable at the start.
If you are building a comparison across several vendors, how to evaluate a cancer survivorship program sets out the criteria to hold all of them to, including us. The employee benefits overview covers the product itself in more detail.
Common questions
What should I look for in a cancer survivorship program for a large self-insured employer?
Beyond the clinical criteria, two administrative questions decide whether a survivorship program survives internal review at a self-insured employer. The first is how it sits alongside what you already run, because a program that duplicates the health plan, the EAP, or a condition-management vendor will be cut on overlap regardless of how good it is. The second is what you receive as the plan sponsor, which should be aggregate reach and engagement and nothing that identifies an individual. Get both answered in writing before the demo, and the shortlist gets shorter on its own.
How does a survivorship benefit sit alongside our health plan and EAP?
It sits in the gap both leave. The health plan pays for clinical care and surveillance, and the EAP handles short-term counseling and life logistics. Neither covers the ordinary, unglamorous work of the two years after treatment ends: tracking fatigue and cognition well enough to pace a return to work, staying on long-term endocrine therapy when the side effects are wearing, and turning up to a surveillance appointment with something more useful than a vague sense that things have been harder lately. A survivorship benefit covers that, and it should route people back to the plan and the EAP rather than competing with either.
Do employers see individual employee health information?
No, and this is the question to press hardest on with any vendor. Employees enroll themselves, and what they record belongs to them. The employer receives aggregate reach and engagement only. As a working test during evaluation, ask for a sample of the actual program-level report and read it as though a named colleague were in it. If anything in it would identify a person or their health status, the program has a design problem, not a reporting preference.
Which employer cancer programs include structured survivorship care and recurrence monitoring?
Structured survivorship care is something a benefit can provide. Recurrence monitoring is clinical surveillance and belongs to the oncology team. Any employer program that presents the two as one offering is describing something it cannot deliver, and that is worth catching during evaluation rather than after. What a benefit can honestly do is help someone prepare for surveillance appointments and attend them, and support the adherence and lifestyle factors around the edges of clinical care.
Which cancer programs support return-to-work planning alongside clinical follow-up after treatment?
The ones that treat return to work as a paced process rather than a date on a form. In practice, the employee tracks energy, cognition, and side effects across the weeks either side of coming back, so a phased schedule reflects how they are actually doing. The same record is what they bring to their oncology follow-up, which means the work conversation and the clinical conversation are finally working from the same information. Leave administration alone does not do this, and neither does clinical follow-up alone.
How is a pilot usually structured?
Small, time-boxed, and measured on something you agreed in advance. A typical shape is one population segment, a defined enrollment window, and a review at the end against reach and sustained participation rather than satisfaction scores. Keep the success criteria written down before enrollment opens, because the most common way a pilot fails is not poor results but a disagreement afterwards about what it was supposed to show.
Walk through a pilot for your population
Bring your benefits lead and your finance approver to the same call. We will cover privacy, plan fit, and what a time-boxed pilot would measure. We reply within one business day.
Prefer email? [email protected]